Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab neoadjuvant therapy for resectable esophageal cancer (real-world study)
ChiCTR2000039170Phase 4Recruiting
- Sponsor
- Quanzhou First Hospital
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in esophageal cancer, sponsored by Quanzhou First Hospital. Primary endpoint: Safety. Started Oct 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2000039170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039170.